<HTML>
Migration of medial smooth<A NAME=4></A> muscle<A NAME=5></A> cells<A NAME=6></A> ( SMCs ) and their proliferation in the intima<A NAME=15></A> contribute<A NAME=16></A> to thickening of injured and atherosclerotic vessels . These events<A NAME=26></A> have been proposed<A NAME=29></A> to be regulated in part by platelet-derived growth<A NAME=37></A> factor<A NAME=38></A> ( PDGF ) . Two separate PDGF receptors have been identified , PDGF-R alpha and PDGF-R beta . To study<A NAME=58></A> the functions<A NAME=60></A> of PDGF-R alpha and PDGF-R beta in vascular SMCs , neutralizing monoclonal antibodies ( mAbs ) specific for each of the two receptors<A NAME=83></A> were used<A NAME=85></A> . These antibodies<A NAME=88></A> allowed<A NAME=89></A> us to evaluate<A NAME=92></A> the role<A NAME=94></A> of each receptor for PDGF-induced proliferation and migration of cultured baboon SMCs . Both PDGF-AA and PDGF-BB stimulated<A NAME=112></A> SMC growth<A NAME=114></A> , with PDGF-BB being more potent than PDGF-AA . Studies with anti-PDGF-R alpha and anti-PDGF-R beta mAbs revealed that both PDGF receptors<A NAME=136></A> promoted<A NAME=137></A> the stimulatory<A NAME=139></A> signals<A NAME=140></A> for proliferation . In contrast , PDGF-BB stimulated<A NAME=148></A> SMC migration<A NAME=150></A> , whereas PDGF-AA had no stimulatory<A NAME=156></A> activity<A NAME=157></A> on its own . Additionally , PDGF-AA was able to suppress<A NAME=168></A> migration<A NAME=169></A> induced<A NAME=170></A> by PDGF-BB or fibronectin in modified Boyden 's chamber<A NAME=179></A> assay<A NAME=180></A> . When PDGF-BB-induced migration was separated into chemotactic and chemokinetic<A NAME=190></A> activities<A NAME=191></A> , only the chemotactic component<A NAME=196></A> was inhibited<A NAME=198></A> by PDGF-AA . The suppression of SMC migration by PDGF-AA was eliminated by anti-PDGF-R alpha<A NAME=213></A> mAb<A NAME=214></A> . In addition , PDGF-BB , in the presence of anti-PDGF-R beta , bound only to PDGF-R alpha and caused<A NAME=234></A> suppression<A NAME=235></A> of SMC migration<A NAME=238></A> induced<A NAME=239></A> by fibronectin . These results<A NAME=244></A> suggest<A NAME=245></A> that when activated by ligand binding , both PDGF-R alpha and PDGF-R beta<A NAME=258></A> stimulate<A NAME=259></A> proliferation<A NAME=260></A> . In contrast , only<A NAME=265></A> activation<A NAME=266></A> of PDGF-R beta<A NAME=269></A> stimulates<A NAME=270></A> migration , whereas ligand binding to PDGF-R alpha<A NAME=278></A> leads<A NAME=279></A> to inhibition of cell<A NAME=283></A> migration<A NAME=284></A> . These observations<A NAME=287></A> provide<A NAME=288></A> support<A NAME=289></A> for the conclusion that PDGF-R alpha and PDGF-R beta may play<A NAME=300></A> different<A NAME=301></A> roles<A NAME=302></A> in SMC function and may be involved in different regulatory<A NAME=312></A> mechanisms<A NAME=313></A> during vascular remodeling . Platelet-derived growth<A NAME=319></A> factor<A NAME=320></A> ( PDGF ) , an agent with important mitogenic effects for bone<A NAME=332></A> cells<A NAME=333></A> , exists in three isoforms , PDGF-AA , -BB , and -AB . PDGF-AB and -BB are the prevalent circulating<A NAME=353></A> isoforms<A NAME=354></A> , whereas normal unstimulated<A NAME=358></A> cells<A NAME=359></A> of the osteoblast<A NAME=362></A> lineage<A NAME=363></A> synthesize<A NAME=364></A> primarily PDGF-AA . We examined<A NAME=369></A> the effects<A NAME=371></A> of PDGF-BB on PDGF-A mRNA expression and PDGF-AA polypeptide<A NAME=380></A> concentrations<A NAME=381></A> in cultures of osteoblast-enriched cells from 22-day-old fetal<A NAME=389></A> rat<A NAME=390></A> calvariae<A NAME=391></A> ( Ob cells ) . In a selected<A NAME=399></A> number<A NAME=400></A> of experiments we compared<A NAME=404></A> the effects<A NAME=406></A> of PDGF-BB with those of PDGF-AA on PDGF-A mRNA<A NAME=415></A> levels<A NAME=416></A> . Steady state PDGF-A mRNA levels<A NAME=422></A> were determined<A NAME=424></A> by Northern<A NAME=426></A> blot<A NAME=427></A> analysis<A NAME=428></A> , and PDGF-AA concentrations<A NAME=432></A> were determined<A NAME=434></A> in acidified and fractionated<A NAME=438></A> culture<A NAME=439></A> medium by a specific RIA for PDGF-A chains . Treatment of Ob cells with PDGF-AA or -BB at 0.3-3.3 nM<A NAME=459></A> caused<A NAME=460></A> a dose-dependent<A NAME=462></A> increase<A NAME=463></A> in steady state PDGF-A mRNA , an effect that was initially observed after 2 h . Treatment with PDGF-BB at 1-3.3 nM for 24 h increased PDGF-AA polypeptide concentrations by 2- to 5-fold . The effects of PDGF on PDGF-A mRNA and polypeptide<A NAME=506></A> levels<A NAME=507></A> were prevented<A NAME=509></A> by the protein synthesis inhibitor<A NAME=514></A> cycloheximide<A NAME=515></A> at 3.6 microM . Phorbol 12-myristate 13-acetate at 1 microM<A NAME=525></A> increased<A NAME=526></A> PDGF-A mRNA<A NAME=528></A> after 2-6 h and PDGF-AA polypeptide levels after 24 h by 2-fold . However , the protein kinase-C inhibitor staurosporine at 50 nM did not modify<A NAME=554></A> basal PDGF-A mRNA<A NAME=557></A> levels<A NAME=558></A> and did not prevent<A NAME=562></A> the stimulatory<A NAME=564></A> effect<A NAME=565></A> of PDGF-AA or -BB on PDGF-A mRNA or PDGF-AA polypeptide<A NAME=575></A> levels<A NAME=576></A> . In conclusion , PDGF-BB and -AA increase skeletal PDGF-A synthesis , an effect that reveals autoinduction of PDGF in bone<A NAME=597></A> cells<A NAME=598></A> . In cultured<A NAME=601></A> rat<A NAME=602></A> vascular smooth<A NAME=604></A> muscle<A NAME=605></A> cells<A NAME=606></A> , platelet-derived<A NAME=608></A> growth<A NAME=609></A> factor ( PDGF ) beta<A NAME=614></A> receptor<A NAME=615></A> was expressed<A NAME=617></A> at a high<A NAME=620></A> level<A NAME=621></A> , whereas PDGF-alpha receptor was not detected . PDGF-BB showed<A NAME=631></A> a high<A NAME=633></A> binding<A NAME=634></A> activity at 4 degrees C in the cells and was not displaced by PDGF-AA or -AB . This result<A NAME=653></A> indicates<A NAME=654></A> that PDGF-AB as well as PDGF-AA does not bind to the cells<A NAME=666></A> lacking<A NAME=667></A> PDGF-alpha receptor<A NAME=669></A> at 4 degrees C. However , at 37 degrees C , PDGF-AB bound to the cells and induced the internalization of PDGF-beta receptor . DNA synthesis was also stimulated potentially by PDGF-AB as well as PDGF-BB in the cells , although PDGF-AA was completely inactive . At 37 degrees C , PDGF-AB caused tyrosine phosphorylation of a group of proteins<A NAME=729></A> including<A NAME=730></A> PDGF-beta receptor and phospholipase C-gamma 1 , but at a slower<A NAME=741></A> rate<A NAME=742></A> than PDGF-BB . At 4 degrees C , PDGF-AB did not stimulate<A NAME=754></A> protein<A NAME=755></A> tyrosine<A NAME=756></A> phosphorylation , whereas PDGF-BB did . A chemical cross-linking experiment showed that PDGF-beta receptor<A NAME=770></A> was dimerized<A NAME=772></A> by PDGF-AB as well as PDGF-BB . These results<A NAME=781></A> indicate<A NAME=782></A> that PDGF-beta receptor<A NAME=785></A> binds<A NAME=786></A> PDGF-AB without participation of PDGF-alpha receptor at 37 degrees C ( but not at 4 degrees C ) , and PDGF-AB as well as PDGF-BB acts as a potent mitogen in the vascular smooth<A NAME=820></A> muscle<A NAME=821></A> cells<A NAME=822></A> . Platelet-derived growth<A NAME=825></A> factor<A NAME=826></A> ( PDGF ) , a potent<A NAME=832></A> mitogen<A NAME=833></A> for mesenchymal cells , consists of PDGF-1 and PDGF-2 polypeptide<A NAME=843></A> chains<A NAME=844></A> which are linked by disulfide<A NAME=849></A> bonds<A NAME=850></A> . Sequence analysis has revealed that : ( a ) the PDGF-2 chain<A NAME=863></A> is encoded<A NAME=865></A> by the c-sis<A NAME=868></A> protooncogene<A NAME=869></A> , the cellular counterpart of the simian<A NAME=876></A> sarcoma<A NAME=877></A> viral oncogene ; ( b ) the PDGF-1 and PDGF-2 chains are related ; and ( c ) the PDGF-1 gene has no known viral homologue . We have previously shown that the PDGF-2 gene<A NAME=912></A> is expressed<A NAME=914></A> during 12-O-tetradecanoylphorbol-13-acetate ( TPA ) induced monocytic differentiation of human HL-60 leukemia<A NAME=926></A> cells<A NAME=927></A> . In the present<A NAME=931></A> study<A NAME=932></A> , PDGF-1 and PDGF-2 gene<A NAME=937></A> expression<A NAME=938></A> was compared<A NAME=940></A> in HL-60 cells , human THP-1 monocytic<A NAME=947></A> leukemia<A NAME=948></A> cells<A NAME=949></A> , and human<A NAME=952></A> monocytes<A NAME=953></A> . Uninduced HL-60 cells , uninduced THP-1 cells , and resting<A NAME=964></A> monocytes<A NAME=965></A> had no detectable PDGF-1 or PDGF-2 mRNA . In contrast , both PDGF-1 and PDGF-2 transcripts were detected in HL-60 cells and monocytes<A NAME=988></A> induced<A NAME=989></A> with TPA , while only PDGF-1 mRNA<A NAME=996></A> was found<A NAME=998></A> in TPA-treated THP-1 cells . Moreover , neither of these transcripts<A NAME=1009></A> were found<A NAME=1011></A> during drug<A NAME=1013></A> induced<A NAME=1014></A> granulocytic differentiation of HL-60 cells . Cycloheximide , an inhibitor of protein synthesis : ( a ) failed to increase PDGF-1 and PDGF-2 mRNA<A NAME=1038></A> levels<A NAME=1039></A> in uninduced HL-60 cells ; ( b ) increased PDGF-2 , but not PDGF-1 , mRNA in resting<A NAME=1057></A> monocytes<A NAME=1058></A> ; and ( c ) increased<A NAME=1064></A> levels<A NAME=1065></A> of PDGF-1 and PDGF-2 mRNA in HL-60 cells and monocytes<A NAME=1075></A> treated<A NAME=1076></A> with TPA . This effect of cycloheximide<A NAME=1083></A> was related<A NAME=1085></A> in part to stabilization of both transcripts . Thus , PDGF-1 and PDGF-2 genes are regulated in myeloid cells , although they share<A NAME=1109></A> common<A NAME=1110></A> control<A NAME=1111></A> mechanisms<A NAME=1112></A> at the post-transcriptional level . Differential regulation of PDGF gene expression would result in altered<A NAME=1127></A> chain<A NAME=1128></A> composition<A NAME=1129></A> of the PDGF protein and possibly changes in biological<A NAME=1138></A> activity<A NAME=1139></A> . Platelet-derived growth<A NAME=1142></A> factor<A NAME=1143></A> ( PDGF ) exists as a homodimer or a heterodimer comprising either PDGF-A or PDGF-B subunits , and each isoform occurs in various<A NAME=1166></A> tissues<A NAME=1167></A> , including<A NAME=1169></A> bone<A NAME=1170></A> . Although the stimulatory effects of PDGF-BB have been studied in cultures of bone cells and intact<A NAME=1187></A> bone<A NAME=1188></A> fragments<A NAME=1189></A> , the influence of other<A NAME=1194></A> isoforms<A NAME=1195></A> that may arise locally or systematically in vivo , has not been reported . Therefore recombinant human PDGF-BB , PDGF-AB , and PDGF-AA were evaluated in osteoblast-enriched<A NAME=1222></A> cultures<A NAME=1223></A> from fetal<A NAME=1225></A> rat<A NAME=1226></A> bone<A NAME=1227></A> . Within 24 hours these factors<A NAME=1233></A> produced<A NAME=1234></A> a graded<A NAME=1236></A> response<A NAME=1237></A> in bone cell DNA and protein synthesis , with half-maximal<A NAME=1247></A> effects<A NAME=1248></A> at approximately 0.6 , 2.1 , and 4.8 nM PDGF-BB , PDGF-AB , and PDGF-AA , respectively . Increases in collagen and noncollagen protein<A NAME=1272></A> synthesis<A NAME=1273></A> were abrogated<A NAME=1275></A> when DNA synthesis was blocked with hydroxyurea . Furthermore , each factor<A NAME=1287></A> reduced<A NAME=1288></A> alkaline phosphatase activity , PDGF-BB being the most inhibitory . Binding<A NAME=1299></A> studies<A NAME=1300></A> with 125I-PDGF-BB or 125I-PDGF-AA and each unlabeled PDGF isoform produced<A NAME=1310></A> discrete<A NAME=1311></A> ligand<A NAME=1312></A> binding<A NAME=1313></A> and displacement<A NAME=1315></A> patterns<A NAME=1316></A> : 125I-PDGF-BB binding was preferentially displaced by PDGF-BB ( Ki approximately 0.7 nM ) , by PDGF-AB ( Ki approximately 2.3 nM ) and poorly by PDGF-AA . In contrast , 125I-PDGF-AA binding was measurably reduced by PDGF-AA ( Ki approximately 4.0 nM ) , but was more effectively displaced by PDGF-BB or PDGF-AB ( each with Ki approximately 0.7 nM ) . These studies<A NAME=1382></A> indicate<A NAME=1383></A> that each PDGF isoform<A NAME=1387></A> produces<A NAME=1388></A> biochemical<A NAME=1389></A> effects<A NAME=1390></A> proportional to binding site occupancy and suggest that receptors that favor PDGF-B subunit binding preferentially mediate<A NAME=1406></A> these results<A NAME=1408></A> in osteoblast-enriched<A NAME=1410></A> bone<A NAME=1411></A> cell cultures . </HTML>
